Table 1 Baseline characteristics of IIH patients
|  | All patients (n = 87) |
|---|---|
Sex, n (%) | |
 Male | 12 (13.8%) |
 Female | 75 (86.2%) |
Age at sample collection (years), median (IQR) | 30.0 (25.0–40.0) |
Disease duration at sample collection (months), median (IQR) | 0 (0–4.0) |
Weight at sample collection (kg), mean ± SD | 104.2 ± 26.5 |
Body mass index (kg/m2), mean ± SD | 37.1 ± 9.8 |
Cardiovascular risk factors other than obesity n (%) | |
 Yes | 16 (18.4%) |
 No | 71 (81.6%) |
Lumbar puncture opening pressure at sample collection (cmH2O), mean ± SD | 34.0 ± 9.6 |
IIH medication at sample collection, n (%) | |
 None | 58 (66.7%) |
 Acetazolamide monotherapy | 23 (26.4%) |
 Acetazolamide + topiramate/furosemide | 6 (6.9%) |
Headache, n (%) | |
 Yes | 70 (80.5%) |
 No | 17 (19.5%) |
Impaired visual acuity, n (%) | |
 Yes | 50 (57.5%) |
 No | 37 (42.5%) |
Visual field defects, n (%) | |
 Yes | 21 (24.1) |
 No | 66 (75.9) |
Diplopia, n (%) | |
 Yes | 7 (8.0%) |
 No | 80 (92.0%) |
Optic nerve sheath diameter (cm), mean ± SD, n = 63 | 0.66 ± 0.07 |